Stock Screener App

Gratuito -

Installare

10.00

5.37% 0.51

after-market

Dopo l'orario di chiusura: 9.71 -0.29 -2.90%

Vir Biotechnology Inc (VIR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché VIR Giù? Forum Previsione

Vir Biotechnology Inc Borsa (VIR) Ultime notizie

Vir Biotechnology prices $150M stock offering at $8.50/share By Investing.com - Investing.com South Africa

Vir Biotechnology prices $150M stock offering at $8.50/share - Investing.com

Vir Biotechnology Announces Pricing of Public Offering of Common Stock - The AI Journal

[144] Vir Biotechnology, Inc. SEC Filing - Stock Titan

Vir Biotechnology Extends Reach with Astellas Collaboration on VIR-5500 - StocksToTrade

Vir Biotechnology leaps on news of Astellas collaboration - The Pharma Letter

Vir Biotechnology (VIR) Receives Maintained Overweight Rating Fr - GuruFocus

Vir Biotechnology (NASDAQ:VIR) Sees Large Volume Increase After Analyst Upgrade - MarketBeat

Vir Biotechnology plans $200 million stock offering - Investing.com India

Vir Biotechnology Announces Proposed Public Offering of Common Stock - BioSpace

A Look At Vir Biotechnology (VIR) Valuation After Astellas Collaboration On VIR-5500 And Early Phase 1 Update - Yahoo Finance

Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 2,089 Shares of Stock - MarketBeat

Insider Selling: Vir Biotechnology (NASDAQ:VIR) CEO Sells 19,039 Shares of Stock - MarketBeat

Verneuil Vanina De Sells 4,445 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat

Insider Selling: Vir Biotechnology (NASDAQ:VIR) CFO Sells 2,089 Shares of Stock - MarketBeat

Aug Big Picture: Can Vir Biotechnology Inc be recession proofJuly 2025 Chart Watch & AI Based Trade Execution Alerts - baoquankhu1.vn

VIR: Needham Raises Vir Biotechnology's Price Target in New Anal - GuruFocus

Vir Biotechnology’s Call Highlights Astellas Deal, VIR-5500 Momentum - TipRanks

Vir Biotechnology launches $200M public stock offering - MSN

These Stocks Are Today’s Movers: AMD, Hims & Hers, Keysight, IBM, Kratos, Vir Biotechnology, Whirlpool, and More - Barron's

VIR Stock Offering Managed by Leading Financial Firms - GuruFocus

Astellas, Vir Biotechnology form partnership on prostate cancer drug By Investing.com - Investing.com South Africa

Vir Biotechnology stock hits 52-week high at 9.88 USD By Investing.com - Investing.com South Africa

Vir Biotechnology plans $200 million stock offering By Investing.com - Investing.com South Africa

Vir Biotechnology (VIR) Stock Surges to 52-Week High on Astellas Deal and Strong Earnings - MEXC

This Small-Cap Biotech Stock Is Soaring 29%. There’s Excitement Over Its Prostate Cancer Drug. - Barron's

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer - The Malaysian Reserve

Morgan Stanley Raises Price Target for VIR to $24 with Overweigh - GuruFocus

Vir Biotechnology: Up On Prostate Data And Astellas DealI'm (Long-Term) Bullish (VIR) - Seeking Alpha

These Analysts Boost Their Forecasts On Vir Biotechnology - Benzinga

Vir Biotechnology, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Astellas and Vir in $1.3B deal for CD3 T-cell engager - bioworld.com

Vir Biotechnology, Inc. Q4 & Full Year 2025 Earnings: Revenue Hits $64.1M on Norgine Deal - Bayelsa Watch

This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug - Barron's

VIR: Evercore ISI Group Raises Price Target to $18, Maintains Ou - GuruFocus

Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High After Earnings Beat - MarketBeat

Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-XTEN - Pharmaceutical Executive

Biotech and Big Tech Drive the Morning Narrative (2026-02-24) - Seeking Alpha

Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday - Benzinga

Vir Biotechnology Secures New Collaboration and Revenue Surge - StocksToTrade

AMD, Hims & Hers, Home Depot, Kratos, Novo Nordisk, IBM, Keysight, Vir Biotechnology, and More Movers - Barron's

This Small-Cap Biotech Stock Is Soaring 26%. There’s Excitement Over Its Prostate Cancer Drug. - Barron's

How a prostate cancer drug and a $1.7 billion deal landed at Vir BioSan Francisco Business Times - The Business Journals

Astellas Pharma, Vir Biotechnology Partner to Advance VIR-5500 - Contract Pharma

Vir Biotechnology stock hits 52-week high at 9.88 USD - Investing.com

Vir Biotechnology’s Strategic Moves Shake Up the Biotech Scene - timothysykes.com

Vir Biotechnology (VIR) Stock: Reaches 52-Week High as Three Big Catalysts Hit at Once - Blockonomi

This Small-Cap Biotech Stock Is Soaring 35%. There’s Excitement Over Its Prostate Cancer Drug. - Barron's

Stock Market Today: S&P 500 Futures Slip As Dow, Nasdaq 100 Gain Following Trump's Tariff Threat — Whirlpool, Uber, HP In Focus (UPDATED) - Benzinga

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits

Why Is Vir Biotechnology Stock Up Today? - TipRanks

Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $18.00 - MarketBeat

Raymond James upgrades Vir Biotechnology stock rating on drug data - Investing.com Australia

Vir Biotechnology Stock Pre-Market (+58%): $1.7B Astellas Deal & Positive Cancer Data - Trefis

AMD, Home Depot, Novo Nordisk, Hims & Hers, Keysight, Vir Biotechnology, and More Movers - Barron's

Vir Biotechnology Secures $335 Million Deal with Astellas for VIR-5500 - Intellectia AI

Vir Biotechnology Stock Pre-Market (+58%) : Landmark Astellas Deal & Positive Cancer Data - Trefis

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Vir Biotechnology, Astellas to Advance Prostate Cancer Treatment; Says Phase 1 Trial Shows 'Promising' Anti-Tumor Activity - marketscreener.com

Vir Biotechnology Stock Hits 52-Week High TuesdayHere's Why - Bitget

Vir Biotechnology (VIR) Surges on Astellas Partnership and Stron - GuruFocus

Vir Biotechnology reports phase 1 trial results for VIR-5500 By Investing.com - Investing.com India

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace

Vir Biotechnology partners with Astellas on prostate cancer drug By Investing.com - Investing.com India

Vir Biotechnology Q4 2025 Earnings Call Transcript - MarketBeat

What’s Happening With VIR Stock? - Forbes

RVMD

$103.24

1.52%

MRNA

$51.37

1.68%

ROIV

$28.66

1.42%

BNTX

$109.84

0.94%

INSM

$148.61

6.31%

ONC

$352.23

4.54%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters